Zieglmayer P, Schmutz R, Lemell P, et al. - Given that Budesolv represents a new aqueous formulation comprising dissolved budesonide demonstrating increased local availability in preclinical models, so, researchers evaluated non‐inferiority of Budesolv vs Rhinocort Aqua 64 (RA) and early onset of action in this study. Among grass pollen allergic rhinoconjunctivitis volunteers (n = 83 (intent‐to‐treat population); n = 75 (per‐protocol population)), Budesolv 10 was compared with RA and placebo in a three‐way cross‐over double‐blinded randomized trial. In terms of Total Nasal Symptom Score and nasal airflow, Budesolv 10 vs RA displayed equal effectiveness following eight days of therapy with a strongly decreased dose (more than 80% reduction). Overall, findings demonstrated a high efficacy of the novel preservative‐free, aqueous low‐dose budesonide formulation even following an initial single treatment. Therefore, Budesolv 10 seemed to have effectiveness as an acute therapy for not only allergic rhinitis but also for allergic rhinitis comorbidities such as mild asthma and conjunctivitis.